Literature DB >> 1538137

Genetic complexity of regulatory mutants defective for HLA class II gene expression.

C Seidl1, C Saraiya, Z Osterweil, Y P Fu, J S Lee.   

Abstract

MHC (called HLA in man) class II genes play an essential role in cell-mediated immunity. Absence of HLA class II Ag on B lymphocytes is the basis of some congenital immunodeficiencies (CID). We have studied CID by generating transient heterokaryons from cell lines of such patients, and we report that the mutations fall into four complementation groups. In addition, fusions with the HLA class II deletion mutant 721.180 indicate that the genetic defects for each group in HLA class II expression map outside the HLA class II region. A small HLA-DRA promoter fragment is sufficient to drive expression of a reporter gene in normal B cell lines, but expression from the same construct is clearly reduced in mutant cell lines representative of all four complementation groups. This confirms earlier results that indicate defective transcription of HLA class II genes in the class II- CID mutant cell lines. Analysis of proteins that bind to the DRA promoter in nuclear extracts of the mutants suggests that complexes recognizing distinct elements of the DRA promoter may be quantitatively decreased in different mutants. In addition, we show that nuclear extracts from two groups fail to transcribe a DRA promoter construct in vitro accurately reflecting their DRA- phenotypes. In contrast, nuclear extracts from another mutant, RJ2.2.5, transcribe the DRA construct, albeit at a reduced level. Finally, though cell lines from different groups complement each other in vivo, no complementation was observed by mixing extracts for transcription in vitro.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1538137

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

Review 1.  The bare lymphocyte syndrome: molecular clues to the transcriptional regulation of major histocompatibility complex class II genes.

Authors:  A DeSandro; U M Nagarajan; J M Boss
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

Review 2.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

3.  Associations and interactions between bare lymphocyte syndrome factors.

Authors:  A M DeSandro; U M Nagarajan; J M Boss
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 4.  Induction of tolerance through mixed chimerism.

Authors:  David H Sachs; Tatsuo Kawai; Megan Sykes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

5.  Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein.

Authors:  S K Mahanta; T Scholl; F C Yang; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

6.  Evolutionary conservation and characterization of the bare lymphocyte syndrome transcription factor RFX-B and its paralogue ANKRA2.

Authors:  Alyssa Bushey Long; Jeremy M Boss
Journal:  Immunogenetics       Date:  2005-01-18       Impact factor: 2.846

7.  Deficient antigen-presenting cell function in multiple genetic complementation groups of type II bare lymphocyte syndrome.

Authors:  S Kovats; G T Nepom; M Coleman; B Nepom; W W Kwok; J S Blum
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

8.  Definition of a novel complementation group in MHC class II deficiency.

Authors:  A Peijnenburg; B Godthelp; A van Boxel-Dezaire; P J van den Elsen
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

9.  The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element.

Authors:  J A Brown; E M Rogers; J M Boss
Journal:  Nucleic Acids Res       Date:  1998-09-15       Impact factor: 16.971

10.  Physiologic target of the Air-1 trans-activator revealed by stable transfection assay.

Authors:  S Sartoris; A De Lerma Barbaro; T Cestari; G Tridente; R S Accolla
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.